Launch of new services powered by TMTpro 16plex

1 July 2019

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Launch of new services powered by TMTpro 16plex

Following the announcement of TMTpro 16plex isobaric mass tags during the American Society for Mass Spectrometry (ASMS) meeting in Atlanta in June, Proteome Sciences is launching upgrades to its core proteomic services (SysQuant^®, TMTcalibrator™ and Plasma Super Depletion) with increased multiplexing. Testing has shown that these new reagents perform equivalently to the current 11-plex TMT^® in terms of the numbers of quantified peptides and proteins, whilst providing a 50% increase in the number of samples that can be analysed in a single experiment.

TMTpro is a completely re-designed set of isobaric mass tags developed and patented by Proteome Sciences, with multiple benefits over the previous TMT reagents. As well as offering five extra channels, the new chemistry also provides a 9-plex set of single-Dalton resolved tags for use with TMT complement ion quantification. In addition, the reporter ion is more readily fragmented and offers gains in signal-to-noise both in MS2 and MS3 analyses.

Adding TMTpro 16-plex reagents to standard service workflows will provide significant benefits to clients in both the size and speed of biomarker discovery projects.

Commenting on the announcement Dr Ian Pike, Chief Scientific Officer, said "We are delighted to be introducing TMTpro into our proprietary biomarker services. Proteome Sciences is the only contract research organisation able to provide clients access to the higher plexing rates and extended performance of TMTpro. This is a critical element enabling the power of proteomics to support larger cohort studies which will be increasingly necessary to deliver precision medicines."

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.